Clinical Trial Update: Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors

View source ↗

Summary

Clinical trial update examining how BRAFV600E intratumor heterogeneity affects treatment of differentiated thyroid cancer with tyrosine kinase inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Snippet

Sponsor: University of Salerno | Conditions: Differentiated Thyroid Cancer | Status: UNKNOWN